Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 07 2022 - 8:05AM
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset
clinical-stage biopharmaceutical company, focused on identifying,
developing and commercializing treatments in high unmet need areas
involving rare diseases and multi-drug resistant (MDR) bacterial
infections, today announced that it will host a conference call and
live audio webcast on Monday, November 14, 2022 at 4:30 p.m. ET to
report its third quarter 2022 financial results and provide an
update on its business and pipeline.
To access the call, please dial 1-855-327-6837
(domestic) or 1-631-891-4304 (international) and refer to
conference ID 10020538. The audio webcast can be accessed under
"Events and Presentations" in the Investor and Media section of the
Company's website at www.sperotherapeutics.com.
The archived webcast will also be available on Spero's website for
30 days following the call.
About Spero TherapeuticsSpero
Therapeutics, headquartered in Cambridge, Massachusetts, is a
multi-asset, clinical-stage biopharmaceutical company focused on
identifying, developing, and commercializing novel treatments for
bacterial infections, including multi-drug resistant bacterial
infections and rare diseases.
- Spero Therapeutics is
developing SPR720 as a novel oral therapy candidate for the
treatment of a rare, orphan pulmonary disease caused by
non-tuberculous mycobacterial infections.
- Tebipenem HBr is an investigational drug in the United States
being developed for the treatment of cUTI, including
pyelonephritis, caused by certain bacteria, in adult patients who
have limited treatment options; tebipenem HBr is not
FDA-approved.
- Spero Therapeutics also has an IV-administered next generation
polymyxin product candidate, SPR206, developed from its potentiator
platform, which is in development to treat multi-drug resistant
Gram-negative infections in the hospital setting.
For more information,
visit https://sperotherapeutics.com.
Investor Relations
Contact: Ted JenkinsVice President, Investor
Relations and Strategic FinanceIR@sperotherapeutics.com (617)
798-4039
Media Inquiries:Lora Grassilli,
Health Media RelationsZeno
Grouplora.grassilli@zenogroup.com646-932-3735
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Sep 2023 to Sep 2024